Oxford Biomedica (OXB.L) traded up 0.59 % during a 24 hours period ending at 02:37 AM Central Europe on Tuesday 27th. One Oxford Biomedica stock can currently be bought for about GBX 527 on popular exchanges. Current supply of Oxford Biomedica stocks is 121.1 mn. Oxford Biomedica has a current market capitalization of GBX 832.4 mn and approximately GBX 132.4 mn worth of Oxford Biomedica was traded on exchanges in the last 24 hours. Since last month end, Oxford Biomedica has traded 4.9 % up. Simple moving average of last 200 days is at GBX 612.17. The highest price of past 52 weeks was recorded at GBX 962 on 01/16/2026. 52 weeks low was at GBX 420 on 09/04/2026.

Here is how related stocks have performed in the past 24 hours:

  • Galliford Try (GFRD.L) traded up 2.7 % and now trades at GBX 697. Current market capitalisation for Galliford Try is GBX 904.9 mn. Galliford Try has a current price to earnings ratio of 17.14.

  • Polar Capital (POLR.L) traded down -1.49 % and now trades at GBX 752. Polar Capital has a market capitalisation of GBX 916 mn. Polar Capital has a current price to earnings ratio of 12.38.

  • Telecom Plus (TEP.L) traded down -0.56 % and now trades at GBX 900. Telecom Plus has a market capitalisation of GBX 912.6 mn. Current price/earnings ratio for Telecom Plus is 8.96.

  • Xps Pensions (XPS.L) traded up 1.04 % and now trades at GBX 343.5. Current market capitalisation for Xps Pensions is GBX 926.2 mn. Xps Pensions has a current price to earnings ratio of 27.26.

  • Avon (AVON.L) traded up 1.28 % and now trades at GBX 2,460. Current market capitalisation for Avon is GBX 935.8 mn. Current price/earnings ratio for Avon is 53.35.

About Oxford Biomedica

Oxford Biomedica PLC is a health care biotechnology company with its base in Oxford, United Kingdom. The company specializes in developing treatments for serious diseases, primarily using its FDA-approved lentiviral vector delivery platform. They work both in vivo and ex vivo, collaborating with global pharmaceutical and biotech partners while building their own portfolio of gene and cell therapy product candidates. You can find more information about their work and products on their website, www.oxfordbiomedica.co.uk , and they are listed on the London Stock Exchange.